Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at StockNews.com

StockNews.com upgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a sell rating to a hold rating in a report issued on Friday.

A number of other equities research analysts have also recently commented on SNDX. Barclays raised their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, August 15th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. UBS Group started coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. Bank of America raised their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, HC Wainwright boosted their target price on Syndax Pharmaceuticals from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $15.83 on Friday. Syndax Pharmaceuticals has a one year low of $14.50 and a one year high of $25.34. The company has a 50-day simple moving average of $18.87 and a two-hundred day simple moving average of $20.21. The firm has a market capitalization of $1.35 billion, a PE ratio of -4.36 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the business earned ($0.73) earnings per share. Analysts expect that Syndax Pharmaceuticals will post -3.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Syndax Pharmaceuticals by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after acquiring an additional 66,459 shares during the last quarter. Barclays PLC lifted its holdings in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after buying an additional 110,535 shares during the period. Y Intercept Hong Kong Ltd increased its stake in shares of Syndax Pharmaceuticals by 319.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock valued at $1,565,000 after buying an additional 61,916 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Syndax Pharmaceuticals by 7.7% in the third quarter. Two Sigma Advisers LP now owns 669,352 shares of the company’s stock valued at $12,885,000 after acquiring an additional 48,100 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in shares of Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock valued at $19,921,000 after acquiring an additional 212,799 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).